38 Week Extension Study to CAIN457C2303



Status:Terminated
Conditions:Cervical Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 100
Updated:4/21/2016
Start Date:March 2010
End Date:January 2011

Use our guide to learn which trials are right for you!

A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)

A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled
study to assess the difference in the rate of recurrent exacerbations in Behçet's patients
with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care
immunosuppressive therapy


Inclusion Criteria:

Exclusion Criteria:
We found this trial at
2
sites
Baltimore, Maryland 21287
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Alexandria,
Click here to add this to my saved trials